Biolegend, 329708, APC anti-human CD274 (B7-H1, PD-L1) Antibody, 100tests

CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.
100tests
Verified Reactivity: Human
Reported Reactivity: African Green, Baboon, Cynomolgus, Rhesus
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Full length human PD-L1
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Red Laser (633 nm)
Application Notes: Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5. Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest. Clone 29E.2A3 does not work in Western blot applications7.
Application References(PubMed link indicates BioLegend citation): Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block) Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block) Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block) Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed Haile, S et al. 2013. J. Immunol. 191:2829. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations: Kuryk L, et al. 2019. Oncoimmunology. 8:e1532763. PubMed Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed Wang J, et al. 2023. ACS Sens. 8:1200. PubMed Pinto C, et al. 2023. iScience. 26:106381. PubMed Lin Z, et al. 2023. J Transl Med. 21:249. PubMed Oreskovic E, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed Thiramanas R, et al. 2020. Cells. 9: . PubMed Miliotis C, et al. 2021. Cancer Lett. 518:115. PubMed Zhang Z, et al. 2022. Cancer Gene Ther. 29:722. PubMed Kwee BJ, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed Yang Z, et al. 2022. Cancer Discov. 12:1942. PubMed Liu C, et al. 2022. Cancer Commun (Lond). 42:828. PubMed Wang Q, et al. 2022. Sci Adv. 8:eabq4722. PubMed Guo Y, et al. 2023. Mol Carcinog. 62:185. PubMed De León Rodríguez SG, et al. 2022. J Oncol. 2022:9775736. PubMed Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed Wang M, et al. 2022. J Cell Biol. 221:. PubMed Pan R, et al. 2022. Cell. 185:1521. PubMed Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed Sapski S, et al. 2020. Cancer Immunol Immunother. 2291:69. PubMed Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed Rauch DA, et al. 2019. Blood. 134:1406. PubMed Sun X, et al. 2020. Am J Cancer Res. 10:564. PubMed Fu Y, et al. 2020. Sci Rep. 10:9027. PubMed Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed Tanaka C, et al. 2021. Molecules. 26:. PubMed Hakroush S, et al. 2021. Front Immunol. 11:624547. PubMed Cen B, et al. 2021. Oncogene. 40:5984. PubMed Leite NC, et al. 2020. Cell Reports. 32(2):107894.. PubMed Cui J, et al. 2020. Cancers (Basel). 0.596527778. PubMed Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed Jiang X, et al. 2013. Clin Cancer Res. 19:598. PubMed Ng W, et al. 2021. Pharm Biol. 59:47:00. PubMed Chou CW, et al. 2020. Am J Cancer Res. 2621:10. PubMed Li C, et al. 2021. J Immunother Cancer. 9:. PubMed Shevyrev D, et al. 2021. Exp Ther Med. 209:21. PubMed Toews K, et al. 2020. Mol Carcinog. 724:59. PubMed Hsu H, et al. 2016. J Immunol. 197: 1884 - 1892. PubMed Bernareggi D, et al. 2022. Nat Commun. 13:1899. PubMed Baleeiro RB, et al. 2022. Oncoimmunology. 11:2080329. PubMed Chen LM, et al. 2021. Biosci Rep. 41:. PubMed Boyerinas B, et al. 2015. Cancer Immunol Res. 3: 1148 - 1157. PubMed Johnson D, et al. 2016. Nat Commun. 7:10582. PubMed Izmirly AM, et al. 2022. PLoS Pathog. 18:e1009903. PubMed Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed Xi X, et al. 2021. Oncol Lett. 22:716. PubMed Kotetsu Y, et al. 2021. Biomedicines. 9:. PubMed Miranda A, et al. 2015. Cancer Res . 75: 3032-3042. PubMed Atefi M, et al. 2014. Clin Cancer Res. 20:3446. PubMed Wallstabe L et al. 2019. JCI Insight. 4(18) pii: 126345. PubMed Su S et al. 2018. Cell. 175(2):442-457 . PubMed Arlt A, et al. 2020. Mol Oncol. 14:571. PubMed Huang BR, et al. 2020. Int J Mol Sci. 21:00. PubMed Yang WH, et al. 2018. Cancer Res. 78:3761. PubMed Chen LM, et al. 2021. Biosci Rep. Online ahead of print. PubMed Fu H, et al. 2021. Front Cell Dev Biol. 9:764109. PubMed Yoshida R, et al. 2022. Cancer Res. :. PubMed Koopmans I, et al. 2018. Oncoimmunology. 7:e1466016. PubMed Lim KH, et al. 2020. Nat Commun. 2.889583333. PubMed Capuano C, et al. 2018. Front Immunol. 9:1031. PubMed Wertel I, et al. 2020. J Immunol Res. 1715064:2020. PubMed Volpin V, et al. 2020. Cancer Immunol Res. 8:1163. PubMed Zhao L, et al. 2018. Oncol Lett. 16:1180. PubMed Jiao S, et al. 2017. Clin Cancer Res. 23:3711. PubMed Palakurthi S, et al. 2019. Cancer Immunol Res. 1.303472222. PubMed Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed Li Z, et al. 2020. Front Cell Dev Biol. 8:572689. PubMed Lin G, et al. 2021. Mol Med Rep. 23:. PubMed Ofori S, et al. 2019. ACS Omega. 4:12584. PubMed Sam J, et al. 2020. Front Oncol. 10:575737. PubMed Jin MH, et al. 2019. Cancer Res Treat. N/A. PubMed Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed Jiang L, et al. 2019. Sci Rep. 9:3705. PubMed Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed Gorris MAJ, et al. 2018. J Immunol. 200:347. PubMed Wang X, et al. 2022. J Exp Clin Cancer Res. 41:210. PubMed Tameishi M, et al. 2021. Pharmaceuticals (Basel). 14:. PubMed Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed O'Connor MH, et al. 2021. Commun Biol. 4:563. PubMed Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed Zheng Y, et al. 2022. Transl Res. :. PubMed Parent AV, et al. 2021. Cell Reports. 36(7):109538. PubMed An L, et al. 2016. Sci Rep. 6: 33346. PubMed Hassounah NB, et al. 2019. Cancer Immunol Immunother. 68:407. PubMed Pawlicki JM, et al. 2021. Cancer Res. 81:3241. PubMed
RRID: AB_940358 (BioLegend Cat. No. 329707) AB_940360 (BioLegend Cat. No. 329708)
Distribution: T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells
Function: CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor: PD-1 (PDCD1)
Cell Type: B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area: Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family: Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
Gene ID: 29126
UniProt: View information about CD274 on UniProt.org
Clone: 29E.2A3
Regulatory Status: RUO
Other Names: Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)
Isotype: Mouse IgG2b, κ